Back to companies

Ionis Pharmaceuticals Inc: Overview

Ionis Pharmaceuticals Inc (Ionis), formerly ISIS Pharmaceuticals, Inc., focuses on the discovery and development of RNA-targeted drugs. The company develops medicines to treat various diseases including cancer, pulmonary, cardiovascular diseases, neurological and infectious diseases. Its major products include Spinraza for spinal muscular atrophy, Tegsedi for neuropathy and Waylivra for familial chylomicronemia syndrome. Ionis also has a pipeline of products in different phases of clinical trials. It develops products based on its proprietary antisense technology. The company partnered with other pharmaceutical companies to develop a range of products in different therapeutic areas. The company sells its products in North America and Europe. Ionis is headquartered in Carlsbad, California, the US.

Headquarters United States of America

Address 2855 Gazelle Ct, Carlsbad, California, 92010-6670


Telephone 1 760 9319200

No of Employees 660

Industry Pharmaceuticals and Healthcare

Ticker Symbol & Exchange IONS (NASD)

Revenue (2021) $810.5M 11.1% (2021 vs 2020)

EPS XXX

Net Income (2021) XXX 93.6% (2021 vs 2020)

Market Cap* $5.4B

Net Profit Margin (2021) XXX 94.2% (2021 vs 2020)

* As of and is in US$

Explore premium data & analytics

200+

Clinical Trials

Determine Ionis Pharmaceuticals Inc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

180+

Catalyst Calendar

Proactively evaluate Ionis Pharmaceuticals Inc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

130+

Pipeline Drugs

Identify which of Ionis Pharmaceuticals Inc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

100+

Lead Sheet

Understand when and why to target accounts of prospective leads, as well as who to reach out to, drawing on intelligence for Ionis Pharmaceuticals Inc’s relevant decision makers and contact details.

50+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

30+

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

14+

Sales & Consensus Forecasts

Understand the current and future drug revenue for Ionis Pharmaceuticals Inc and assess market opportunity for new entrants with patient population 8-year forecasts.

1

Marketed Drugs

Understand Ionis Pharmaceuticals Inc’s commercialized product portfolio to stay one step ahead of the market.

Subscribe to Company Analytics & gain access to premium industry data & analytics Subscribe to Company Analytics & gain access to premium industry data & analytics Start Here

Products and Services

Products Brands
Nusinersen - Spinal Muscular Atrophy Spinraza
Inotersen - Polyneuropathy Tegsedi
Volanesorsen - Familial Chylomicronemia Syndrome Waylivra
XXX
XXX
XXX
Subscribe to Company Analytics for access to more products & services data Subscribe to Company Analytics for access to more products & services data Learn More

History

History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.

Year Event Description
2022 Official Trials/Tests In June, the company and AstraZeneca's eplontersen meets endpoints in Phase III ATTRv-PN trial.
2022 Regulatory Approval In January, the company announced U.S. Food and Drug Administration (FDA) granted orphan drug designation to eplontersen.
2022 Others In January, the company announced Biogen to obtain licence for Ionis’ investigational investigational antisense oligonucleotide (ASO), BIIB115/ION306.
Dive into past operations, including product releases, deals, acquisitions & more Dive into past operations, including product releases, deals, acquisitions & more Get Started
Image for loader

Competitor Comparison

Key Parameters Ionis Pharmaceuticals Inc Alnylam Pharmaceuticals Inc Intercept Pharmaceuticals Inc Arrowhead Pharmaceuticals Inc Enzo Biochem Inc
Headquarters United States of America United States of America United States of America United States of America United States of America
City Carlsbad Cambridge Morristown Pasadena Farmingdale
State/Province California Massachusetts New Jersey California New York
No. of Employees 660 1,665 437 329 451
Entity Type Public Public Public Public Public
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more

Key Financial Charts

Operating Margin
Operating Margin
EPS (Earnings per Share)
EPS (Earnings per Share)
Debt to Equity Ratio
Debt to Equity Ratio
Return on Assets
Return on Assets
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
Joseph Loscalzo, M.D., Ph.D. Chairman Executive Board 2021 70
Brett P. Monia, Ph.D. Chief Executive Officer; Director Executive Board 2020 60
Elizabeth L. Hougen Chief Financial Officer; Executive Vice President - Finance Senior Management 2013 60
Patrick R. O’Neil General Counsel; Secretary; Chief Legal Officer Senior Management 2021 48
C. Frank Bennett, Ph.D. Chief Scientific Officer; Executive Vice President Senior Management 2020 65
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Non Dignissim Eros Proin vel Convallis 2022 XX
Gain more insight into company management & employee structure with Company Analytics Gain more insight into company management & employee structure with Company Analytics Subscribe
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer